Cargando…

Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report

Introduction: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection that causes novel Coronavirus Disease 2019 (COVID-19) has become a major health problem worldwide and been declared a pandemic since March 2020 by WHO. One special population that poses a challenge is pregnant wome...

Descripción completa

Detalles Bibliográficos
Autores principales: Saroyo, Yudianto Budi, Rumondang, Amanda, Febriana, Irene Sinta, Harzif, Achmad Kemal, Irwinda, Rima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162322/
https://www.ncbi.nlm.nih.gov/pubmed/34067822
http://dx.doi.org/10.3390/idr13020042
_version_ 1783700686396981248
author Saroyo, Yudianto Budi
Rumondang, Amanda
Febriana, Irene Sinta
Harzif, Achmad Kemal
Irwinda, Rima
author_facet Saroyo, Yudianto Budi
Rumondang, Amanda
Febriana, Irene Sinta
Harzif, Achmad Kemal
Irwinda, Rima
author_sort Saroyo, Yudianto Budi
collection PubMed
description Introduction: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection that causes novel Coronavirus Disease 2019 (COVID-19) has become a major health problem worldwide and been declared a pandemic since March 2020 by WHO. One special population that poses a challenge is pregnant women with COVID-19. There have not been many studies related to COVID-19 in pregnancy. In this study, we present five serial cases of Remdesivir treatment for COVID-19 in pregnant women with moderate to severe symptoms. Case Illustration: We briefly describe five serial cases being treated with Remdesivir therapy during hospitalization. Four cases were delivered by cesarean section, and one was delivered vaginally in gestation week 37. All cases showed a shortened duration of hospitalization, rapid improvement in clinical symptoms, and no adverse events were observed in mothers, fetuses, and neonates. Discussion: Remdesivir, an inhibitor RNA Polymerase, has been used in COVID-19 treatment and is known to shorten recovery time in nonpregnant women. Some studies have shown no adverse effects on Remdesivir for pregnant women. Based on randomized control trial (RCT) during the Ebola epidemic, Remdesivir was safe to use for pregnant women. All cases showed reduced hospitalization time and better clinical outcomes without maternal, fetal, or neonatal adverse events. Conclusion: Remdesivir protocol for pregnant women with moderate to severe symptoms of COVID-19 has resulted in better clinical improvement with a shorter recovery period and no adverse effects during the hospitalization period. Further studies and RCT are warranted to evaluate the biosafety and effects of Remdesivir in pregnant women.
format Online
Article
Text
id pubmed-8162322
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81623222021-05-29 Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report Saroyo, Yudianto Budi Rumondang, Amanda Febriana, Irene Sinta Harzif, Achmad Kemal Irwinda, Rima Infect Dis Rep Case Report Introduction: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection that causes novel Coronavirus Disease 2019 (COVID-19) has become a major health problem worldwide and been declared a pandemic since March 2020 by WHO. One special population that poses a challenge is pregnant women with COVID-19. There have not been many studies related to COVID-19 in pregnancy. In this study, we present five serial cases of Remdesivir treatment for COVID-19 in pregnant women with moderate to severe symptoms. Case Illustration: We briefly describe five serial cases being treated with Remdesivir therapy during hospitalization. Four cases were delivered by cesarean section, and one was delivered vaginally in gestation week 37. All cases showed a shortened duration of hospitalization, rapid improvement in clinical symptoms, and no adverse events were observed in mothers, fetuses, and neonates. Discussion: Remdesivir, an inhibitor RNA Polymerase, has been used in COVID-19 treatment and is known to shorten recovery time in nonpregnant women. Some studies have shown no adverse effects on Remdesivir for pregnant women. Based on randomized control trial (RCT) during the Ebola epidemic, Remdesivir was safe to use for pregnant women. All cases showed reduced hospitalization time and better clinical outcomes without maternal, fetal, or neonatal adverse events. Conclusion: Remdesivir protocol for pregnant women with moderate to severe symptoms of COVID-19 has resulted in better clinical improvement with a shorter recovery period and no adverse effects during the hospitalization period. Further studies and RCT are warranted to evaluate the biosafety and effects of Remdesivir in pregnant women. MDPI 2021-05-17 /pmc/articles/PMC8162322/ /pubmed/34067822 http://dx.doi.org/10.3390/idr13020042 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Saroyo, Yudianto Budi
Rumondang, Amanda
Febriana, Irene Sinta
Harzif, Achmad Kemal
Irwinda, Rima
Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title_full Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title_fullStr Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title_full_unstemmed Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title_short Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
title_sort remdesivir treatment for covid 19 in pregnant patients with moderate to severe symptoms: serial case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162322/
https://www.ncbi.nlm.nih.gov/pubmed/34067822
http://dx.doi.org/10.3390/idr13020042
work_keys_str_mv AT saroyoyudiantobudi remdesivirtreatmentforcovid19inpregnantpatientswithmoderatetoseveresymptomsserialcasereport
AT rumondangamanda remdesivirtreatmentforcovid19inpregnantpatientswithmoderatetoseveresymptomsserialcasereport
AT febrianairenesinta remdesivirtreatmentforcovid19inpregnantpatientswithmoderatetoseveresymptomsserialcasereport
AT harzifachmadkemal remdesivirtreatmentforcovid19inpregnantpatientswithmoderatetoseveresymptomsserialcasereport
AT irwindarima remdesivirtreatmentforcovid19inpregnantpatientswithmoderatetoseveresymptomsserialcasereport